Late-stage studies of a potentially blockbuster experimental Alzheimer's drug called Dimebon, revealed the pill worked at the same level as the placebo in improving thinking clarity and daily function. The drug, developed by Pfizer Inc. with partner Medivation Inc. had exhibited potential at preventing symptoms of the disease from deepening for a year in prior studies. Positive indicators early on led the pharmaceutical companies, investors and others to develop high expectations for the drugs performance in late stage studies and should it be released, on the market, were it released.
The drug; however, failed to meet primary and secondary goals. Dimebon had been a major prospect for the company. While not dead in the water, enthusiasm for Dimebon has waned significantly. The drug is still being studied to asses what potential it has when working in conjunction with other Alzheimer’s treatments or when used for an extended period.
Prior to the new results, Dimebon had been the Pfizer product closest to approval.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription
